BV02

BV02 is a 14-3-3 inhibitor and an antibacterial agent. BV02 enhances the cleavage of PARP and caspase-3. BV02 induces Apoptosis, Autophagy, and enhances Akt activation. BV02 has anti-B. melitensis infection and epilepsy-promoting effects. BV02 can also be used in colitis research.

292870-53-2

12352005

H400

Akt; Apoptosis; Autophagy; Bacterial; Caspase; PARP

Reference compound

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR

Cancer-programmed cell death

Infection; Inflammation/Immunology; Neurological Disease

https://www.medchemexpress.com/bv02.html

99.75

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

O=C(C1=CC2=C(C(N(C3=C(C)N(C)N(C4=CC=CC=C4)C3=O)C2=O)=O)C=C1)O

C20H15N3O5

377.36

H400

[1]Mancini M, et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther. 2011 Mar;336 (3) :596-604.|[2]Fernández-Orth J, et al. 14-3-3 Proteins regulate K2P 5.1 surface expression on T lymphocytes. Traffic. 2017 Jan;18 (1) :29-43. |[3]Kim HJ, et al. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells. Oncotarget. 2017 Jan 24;8 (4) :6608-6622.|[4]Gómez-Suárez M, et al. 14-3-3 Proteins regulate Akt Thr308 phosphorylation in intestinal epithelial cells. Cell Death Differ. 2016 Jun;23 (6) :1060-72.|[5]Wen Y, et al. HAP1 interacts with 14-3-3 to regulate epileptic seizure via GABAAR-mediated inhibitory synaptic transmission in pentylenetetrazole rat model. Neurosci Res. 2022 Sep;182:7-14.|[6]Joshi K, et al. Brucella targets the host ubiquitin-specific protease, Usp8, through the effector protein, TcpB, for facilitating infection of macrophages. Infect Immun. 2024 Feb 13;92 (2) :e0028923.

Room Temperature

-20°C, 3 years; 4°C, 2 years (Powder)

Reference compound1

No Development Reported